Restricted accessResearch articleFirst published online 2025-5
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments
Patients with refractory conditions often identify themselves with their illness, which affects multiple aspects of their lives. The pictorial representation of illness and self measure (PRISM) is a tool used to assess the enmeshment of individuals’ perception of self with a particular medical condition, broadly termed self-condition enmeshment.
Aims:
This study aimed to evaluate changes in PRISM scores and how these changes relate to symptom changes following naturalistic psychedelic use.
Methods:
In this survey, we retrospectively assessed changes in PRISM scores in 297 individuals who self-engaged in naturalistic psychedelic use for therapeutic purposes. Participants also completed the Patient Global Impression of Change (PGIC) scale to report symptom changes resulting from their perceived most salient psychedelic experience (MSPE).
Results:
PGIC scores indicated that the majority of participants with depression (95.4%), posttraumatic stress disorder (98.36%), and anxiety (94.87%) reported symptom improvement following naturalistic psychedelic use. There was a significant decrease (p = 4.65 × 10−25) in PRISM scores after MSPE compared to their PRISM scores before MSPE, indicating that individuals experienced a reduced identification of their identity with their condition following psychedelic use. PRISM change scores were also correlated with PGIC scores across all conditions (ρ = 0.41, p = 1.64 × 10−11), indicating that reductions in self-condition enmeshment were associated with symptom improvement.
Conclusions:
Our results suggest that PRISM has transdiagnostic sensitivity for investigating the effects of psychedelics on self-perception. Interpretation is limited by convenience sampling, potential positive bias, retrospective reporting, and unclear doses and settings with natural psychedelic use.
AdayJSMitzkovitzCMBloeschEK, et al. (2020) Long-term effects of psychedelic drugs: A systematic review. Neurosci Biobehav Rev113: 179–189.
2.
BogenschutzMPRossSBhattS, et al. (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry79: 953–962.
3.
BorghiAFlaccoMEMontiA, et al. (2022) Assessment of the perceived burden associated with Malignant Melanoma with Pictorial Representation of Illness and Self Measure (PRISM) and Melanoma Concerns Questionnaire (MCQ-28). Support Care Cancer30: 3643–3653.
4.
BorghiAFlaccoMEZeddeP, et al. (2023) Does clearance of vulvar lichen sclerosus after a corticosteroid treatment correspond to a decrease in disease-related burden? Results from a cohort study using pictorial representation of illness and self-measure and the dermatology life quality index. Dermatology239: 81–90.
5.
BremlerRKatatiNShergillP, et al. (2023) Case analysis of long-term negative psychological responses to psychedelics. Sci Rep13: 15998.
6.
BüchiSSenskyT (1999) PRISM: Pictorial Representation of Illness and Self Measure: A brief nonverbal measure of illness impact and therapeutic aid in psychosomatic medicine. Psychosomatics40: 314–320.
7.
BüchiSBuddebergCKlaghoferR, et al. (2002) Preliminary validation of PRISM (Pictorial Representation of Illness and Self Measure)–A brief method to assess suffering. Psychotherapy Psychosomatics71: 333–341.
8.
BüssingAOstermannTNeugebauerEA, et al. (2010) Adaptive coping strategies in patients with chronic pain conditions and their interpretation of disease. BMC Public Health10: 507.
9.
CasierAGoubertLGebhardtWA, et al. (2013) Acceptance, well-being and goals in adolescents with chronic illness: A daily process analysis. Psychol Health28: 1337–1351.
10.
ChristensenJFDi CostaSBeckB, et al. (2019) I just lost it! Fear and anger reduce the sense of agency: A study using intentional binding. Exp Brain Res237: 1205–1212.
11.
DaiRLarkinTEHuangZ, et al. (2023) Classical and non-classical psychedelic drugs induce common network changes in human cortex. NeuroImage273: 120097.
12.
DavisAKBarrettFSMayDG, et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry78: 481–489.
13.
dos SantosRGOsórioFdeLRochaJM, et al. (2021) Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: A pilot, proof-of-concept, randomized, placebo-controlled trial. J Clin Psychopharmacol41: 540.
14.
DworkinRHAndersonBTAndrewsN, et al. (2022) If the doors of perception were cleansed, would chronic pain be relieved? evaluating the benefits and risks of psychedelics. J Pain23: 1666–1679.
15.
Garcia-RomeuAKersgaardBAddyPH (2016) Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol24: 229–268.
16.
GasserPHolsteinDMichelY, et al. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nervous Mental Disease202: 513–520.
17.
GluePNeehoffSSabadelA, et al. (2020) Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol34: 267–272.
18.
GlynosNGAdayJSKrugerD, et al. (2024) Psychedelic substitution: Altered substance use patterns following psychedelic use in a global survey. Front Psychiatry15: 1349565.
19.
GreenwayKT (2023) Context is a critical for psychoactive drug effects. CNS Drugs37: 1065–1068.
20.
GriffithsRRRichardsWAMcCannU, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology187: 268–283.
21.
GuyW (1976) Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology, National Institute of Mental Health, Rockville, pp. 217–222.
22.
InselTCuthbertBGarveyM, et al. (2010a) Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry167: 748–751.
23.
InselTCuthbertBGarveyM, et al. (2010b) Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am J Psychiatry167: 748–751.
JohnsonMWGarcia-RomeuAGriffithsRR (2017) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse43: 55–60.
26.
KassardjianCDGardner-NixJDupakK, et al. (2008) Validating PRISM (Pictorial Representation of Illness and Self Measure) as a measure of suffering in chronic non-cancer pain patients. J Pain9: 1135–1143.
27.
KokTDe HaanHASenskyT, et al. (2017) Using the pictorial representation of illness and self measure (PRISM) to quantify and compare suffering from trauma and addiction. J Dual Diagnosis13: 101–108.
28.
Kursawe LarsenCKjaersgaard AndersenRKirbyJS, et al. (2021) Convergent validity of suffering and quality of life as measured by the hidradenitis suppurativa quality of life. J Eur Acad Dermatol Venereol35: 1577–1581.
29.
KurtzJSPatelNAGendreauJL, et al. (2022) The use of psychedelics in the treatment of medical conditions: An analysis of currently registered psychedelics studies in the American drug trial registry. Cureus14: e29167.
30.
LehmannVOerlemansSvan de Poll-FranseLV, et al. (2011) Suffering in long-term cancer survivors: An evaluation of the PRISM-R2 in a population-based cohort. Qual Life Res20: 1645–1654.
31.
LiWZhouYLiuW, et al. (2022) Long-term outcomes of repeated ketamine infusions in patients with unipolar and bipolar depression: A naturalistic follow-up study. J Affective Disord300: 172–178.
32.
MandalSSinhaVKGoyalN (2019) Efficacy of ketamine therapy in the treatment of depression. Indian J Psychiatry61: 480–485.
33.
MendesFRCostaCdosSWiltenburgVD, et al. (2022) Classic and non-classic psychedelics for substance use disorder: A review of their historic, past and current research. Addict Neurosci3: 100025.
34.
MitchellJMOt’aloraG. Mvan der KolkB, et al. (2023) MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial. Nat Med29: 2473–2480.
35.
MooreJW (2016) What is the sense of agency and why does it matter?Front Psychol7: 1272.
36.
NaganumaKOeMIshidaT, et al. (2024) Visual assessment of therapeutic relationships in psychiatric patients: A pilot study using the pictorial representation of illness and self measure. Kurume Med J69: 159–165.
NorbergA (2019) Sense of Self among Persons with Advanced Dementia. In: TWisniewski (ed.) Alzheimer’s Disease. Brisbane (AU): Codon Publications. Available at: http://www.ncbi.nlm.nih.gov/books/NBK552152/ (accessed 14 June 2024).
39.
NorthoffG (2014) How is our self altered in psychiatric disorders? A neurophenomenal approach to psychopathological symptoms. Psychopathology47: 365–376.
40.
OvergaardMPrestonCAspellJ (2023) The self, its body and its brain. Sci Rep13: 12761.
41.
Palhano-FontesFBarretoDOniasH, et al. (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psycholog Med49: 655–663.
42.
PaschaliMLazaridouAVilsmarkES, et al. (2021) The ‘self’ in pain: High levels of schema-enmeshment worsen fibromyalgia impact. BMC Musculoskeletal Disord22: 871.
43.
PouyanNHalvaei KhankahdaniZYounesi SisiF, et al. (2022a) A research domain criteria (RDoC)-guided dashboard to review psilocybin target domains: A systematic review. CNS Drugs36: 1031–1047.
44.
PouyanNHalvaei KhankahdaniZYounesi SisiF, et al. (2022b) A research domain criteria (RDoC)-guided dashboard to review psilocybin target domains: A systematic review. CNS drugs. Epub ahead of print 12 September 2022. DOI: 10.1007/s40263-022-00944-y.
45.
PouyanNYounesi SisiFKargarA, et al. (2023) The effects of lysergic acid diethylamide (LSD) on the positive valence systems: A research domain criteria (RDoC)-informed systematic review. CNS Drugs37: 1027–1063.
46.
PrellerKHVollenweiderFX (2018) Phenomenology, structure, and dynamic of psychedelic states. In: ALHalberstadtFXVollenweiderDENichols (eds) Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Berlin, Heidelberg: Springer, pp. 221–256. Available at: https://doi.org/10.1007/7854_2016_459 (accessed 20 October 2023).
47.
ReinhardtSBischofGGrothuesJ, et al. (2006) Performance of the pictorial representation of illness and self measure in individuals with alcohol dependence, alcohol abuse or at-risk drinking. Psychotherapy Psychosomatics75: 249–256.
48.
RenderAJansenP (2019) Dopamine and sense of agency: Determinants in personality and substance use. PLoS ONE14: e0214069.
49.
Román-CalderónJPGonzales-MirandaDRGalloO, et al. (2020) Using PRISM to test amotivation as a mediator between work-home and turnover. TPM-Testing Psychometrics Methodology Appl Psychol27: 171–184.
50.
Rotz RvonSchindowskiEMJungwirthJ, et al. (2023) Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine56: 101809.
51.
SchmalzGSchmidtLHaakR, et al. (2022) PRISM (Pictorial Representation of Illness and Self-Measure) as visual tool to support oral health education prior to endoprosthetic joint replacement-a novel approach in dentistry. J Clin Med11, 11(9), 2508.
52.
SiegelJSSubramanianSPerryD, et al. (2024) Psilocybin desynchronizes the human brain. Nature632: 131–138.
53.
SoaresCGonzaloGCastelhanoJ, et al. (2023) The relationship between the default mode network and the theory of mind network as revealed by psychedelics – a meta-analysis. Neurosci Biobehav Rev152: 105325.
54.
StuderusEGammaAVollenweiderFX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE5: e12412.
55.
TomiokaMHosoiMOkuzawaT, et al. (2021) The effectiveness of Pictorial Representation of Illness and Self Measure (PRISM) for the assessment of the suffering and quality of interpersonal relationships of patients with chronic pain. BioPsychoSocial Med15: 22.
56.
TurnerJKellyB (2000) Emotional dimensions of chronic disease. Western J Med172: 124–128.
WeijersARasingSCreemersD, et al. (2022) Deconstructing recovery: A prospective study on well-being, symptom severity and acceptance in patients with major depressive disorders. J Affect Disord296: 653–659.
59.
WittmannLSchnyderUBüchiS (2012a) PRISM (Pictorial Representation of Illness and Self Measure): A new method for the assessment of suffering after trauma. J Traumatic Stress25: 94–97.
60.
WittmannLSchnyderUBüchiS (2012b) PRISM (Pictorial Representation of Illness and Self Measure): A new method for the assessment of suffering after trauma. J Traum Stress25: 94–97.
61.
WolfsonPEAndriesJFeducciaAA, et al. (2020) MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Sci Rep10: 20442.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
